Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 3/9/2019 |
| Start Date: | April 1, 2019 |
| End Date: | July 1, 2021 |
| Contact: | Karen Posey, PhD |
| Email: | karen.posey@uth.tmc.edu |
| Phone: | 7135005786 |
The purpose of this study is to determine if self-administered oral resveratrol can dampen
joint pain for individuals with pseudoachondroplasia compared to placebo.
joint pain for individuals with pseudoachondroplasia compared to placebo.
Inclusion Criteria:
- The diagnosis of pseudoachondroplasia is based on clinical assessment either in person
or by photographic review by skeletal dysplasia specialist (JTH),
- Healthy beyond pseudoachondroplasia associated complications,
Exclusion Criteria:
- Current use of resveratrol
- Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine
and triazolam.
- Other non-pseudoachondroplasia related health conditions, e.g. cancers.
- Pregnancy or breastfeeding. Women must use adequate contraception during the study.
- Participation in another clinical study and/or using investigational agents.
- Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.
- Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine,
Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir,
Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine,
Fosphenytoin, Phenytoin or Warfarin.
- Baseline level of pain of 2 or higher on 10 point scale.
- Platelet count below 50,000 per ul on baseline complete blood count (CBC).
We found this trial at
1
site
Click here to add this to my saved trials
